AstraZeneca dragout Entasis files to fund antibiotic phase 3 for USD 86 Million IPO
Massachusetts-based Entasis Therapeutics has spun out to raise up to USD 86 Million through an IPO. The AstraZeneca spinout is attempting to fund a phase 3 trial of a drug to overcome bacterial resistance to beta-lactams. In 2015, Entasis spun out of AstraZeneca with an antibiotic drug discovery platform. Since then, Entasis has requested USD 86 Million from Clarus Lifesciences, Novo Holdings and Frazier Life Sciences, that enables it to lead candidate to the cusp of phase 3.
Sierra remunerates Gilead late-stage cancer drug with just USD 3 Million upfront
Sierra Oncology reimburses ...
